Innovent Biologics, Inc., a biopharmaceutical firm specializing in the development, manufacturing, and commercialization of high-quality medicines, has recently announced IBI322 Phase I study results in patients suffering from advanced solid tumors.  

Introduced at the AACR (American Association for Cancer Research) Annual Meeting 2022, this is a first-in-human, phase Ia/Ib dose-expansion/escalation study of IBI322 monotherapy in advanced solid tumors patients who have failed standard care treatment.

Around 58 subjects were registered for the study, of which 16 had earlier received PD-1/L1 treatment.

As per the study, IBI322 showcased favorable efficacy results, tolerability and safety profile. The study was also conducted for exploring the efficacy and safety of IBI322 in several signs.

Professor Jie Wang, Chief of the Department of Medical Oncology, Cancer Hospital and principal investigator of the study at the Peking Union Medical College and Chinese Academy of Medical Sciences, stated that ICI (immune checkpoint inhibitors) has witnessed favorable efficacy in various types of tumors; however, many clinical challenges remain the same.

With the growing use of ICI in the first-line setting, several patients established ICI resistance or possessed a poor response rate in clinical practice. Thereby, it is a significant clinical implication for developing leading-edge inhibitors with the bi-specific immune checkpoint.

With modernized bispecific development of antibody technology, IBI322 has witnessed favorable safety and introductory efficacy signals in subjects who have failed the previous standard treatment, increasing the firm’s confidence in expanding the cohort study, said Prof. Wang.

Dr. Hui Zhou, VP of Innovent, said that the company will continue to move forward with the phase Ib expansion cohort study and explore the efficacy and safety of IBI322 in multiple indications. Developing an advanced pipeline of next-gen immune checkpoint inhibitors, Innovent aims to bring medical benefit to more patients.

Source Credit - https://www.prnewswire.com/news-releases/innovent-release-phase-1-results-of-ibi322-anti-pd-l1cd47-bispecific-antibody-in-patients-with-advanced-solid-tumors-at-aacr-annual-meeting-2022-301522318.html